3D Medicines, Inc. (HK:1244) has released an update.
3D Medicines Inc. has announced its intention to adopt a Chinese name to bolster its presence and corporate identity in the Greater China market, a move considered beneficial for future business development. Shareholders’ rights and the company’s financial position will remain unaffected by this change, and existing share certificates will continue to be valid. Additionally, the company has rescheduled its Annual General Meeting (AGM) to June 28, 2024, and will close its register of members for a short period around this date to determine attendee eligibility.
For further insights into HK:1244 stock, check out TipRanks’ Stock Analysis page.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
